checkAd
    Biocryst Pharmaceuticals Aktie
    4,3800
     
    USD
    -0,68 %
    -0,0300 USD
    Letzter Kurs 02:00:00 Nasdaq
    4,3700
     
    USD
    59.100 STK
    Geldkurs 23.04.24
    4,3800
     
    USD
    15.400 STK
    Briefkurs 23.04.24
    ISIN: US09058V1035 · WKN: 896047 · SYM: BCRX · USA

    Neueste Nachrichten

    Fokus Aktien mit extremen Handelsvolumen am Dienstag, den 23.04.2024
    23.04.24 · wO Chartvergleich · AGROB Immobilien
    BioCryst to Report First Quarter 2024 Financial Results on May 6
    22.04.24 · globenewswire · Biocryst Pharmaceuticals
    BioCryst Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency
    17.04.24 · globenewswire · Biocryst Pharmaceuticals
    BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    03.04.24 · globenewswire · Biocryst Pharmaceuticals
    BioCryst to Present at Upcoming Investor Conferences
    25.03.24 · globenewswire · Biocryst Pharmaceuticals
    BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    05.03.24 · globenewswire · Biocryst Pharmaceuticals
    BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
    26.02.24 · globenewswire · Biocryst Pharmaceuticals
    BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO (berotralstat) Treatment
    23.02.24 · globenewswire · Biocryst Pharmaceuticals
    BioCryst to Present at Upcoming Investor Conferences
    21.02.24 · globenewswire · Biocryst Pharmaceuticals
    BioCryst Launches ORLADEYO (berotralstat) in Italy
    19.02.24 · globenewswire · Biocryst Pharmaceuticals
    BioCryst to Report Fourth Quarter 2023 Financial Results on February 26
    12.02.24 · globenewswire · Biocryst Pharmaceuticals
    BioCryst to Present New ORLADEYO (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
    05.02.24 · globenewswire · Biocryst Pharmaceuticals